Henlez develops biologic therapies specifically targeting recurrent and follicular skin disorders, utilizing advanced formulations to enhance skin health. The company aims to provide effective treatment options that improve patient outcomes and reduce the frequency of flare-ups.
Funding
$988.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KFounders
Product
Problem
Recurrent and follicular skin disorders, such as hidradenitis suppurativa, significantly impact patients' quality of life due to persistent inflammation, pain, and disfigurement. Current treatments often provide limited relief and can have undesirable side effects, creating a need for more targeted and effective therapies.
Solution
Henlez is developing biologic therapies designed to specifically address recurrent and follicular skin disorders. Their approach involves advanced formulations that aim to enhance skin health by targeting the underlying biological mechanisms of these conditions. By focusing on the root causes of flare-ups, Henlez seeks to provide effective treatment options that improve patient outcomes and reduce the frequency of disease recurrence. The company's research and development efforts are centered on creating innovative solutions that offer sustained relief and minimize the adverse effects associated with existing treatments.
Target Audience
The primary target audience includes individuals suffering from recurrent and follicular skin disorders, such as hidradenitis suppurativa, and the dermatologists who treat them.
Features
- Development of biologic therapies for recurrent skin disorders
- Advanced formulations targeting the biological mechanisms of skin diseases
- Focus on hidradenitis suppurativa (HS)